Introduction
Compliance with Ethics Guidelines
Pharmacological and Functional Selectivity Profile
Non α1-AR subtype selective | α1-AR subtype selective | ||
---|---|---|---|
Prazosin | Tamsulosin | Silodosin | |
Affinity for human α1A-AR subtype, mean K
i
value (nmol/L) | 0.12 | 0.012 | 0.039 |
Affinity for human α1B-AR subtype, mean K
i
value (nmol/L) | 0.028 | 0.12 | 6.5 |
Affinity for human α1D-AR subtype, mean K
i
value (nmol/L) | 0.078 | 0.030 | 2.2 |
α1-AR subtype selectivity α1A/α1B ratio | 0.204 | 9.55 | 162 |
Functional uroselectivity (ED15/ID50) | 0.196 | 2.24 | 11.7 |
Clinical Efficacy and Safety
Urodynamic Efficacy
Clinical Efficacy Profile
Author | Study design | Treatment | Duration (weeks) | Population (n) | Mean Δ total IPSS | Mean Δ Qmax (mL/s) |
---|---|---|---|---|---|---|
Yu et al. [18] | Multicenter, randomized, double-blind | Silodosin 4 mg bd Tamsulosin 0.2 mg od | 12 | 105 | −10.6 | +0.9 |
104 | −10.0 | +1.6 | ||||
Kawabe et al. [19] | Multicenter, randomized, double-blind, placebo controlled | Silodosin 4 mg bd Tamsulosin 0.2 mg od Placebo | 12 | 176 | −8.3a
| +1.7a
|
192 | −6.8 | +2.6 | ||||
89 | −5.3 | +0.2 | ||||
Chapple et al. [16] | Multicenter, double-blind, placebo controlled | Silodosin 8 mg od Tamsulosin 0.4 mg od Placebo od | 12 | 381 | −7.0a
| +3.77 |
384 | −6.7a
| +3.53 | ||||
190 | −4.7 | +2.93 | ||||
Marks et al. [21] | Pooled analysis of two multicenter, randomized, placebo-controlled studies | Silodosin 8 mg od Placebo | 12 | 466 | −6.4a
| +2.6a
|
457 | −3.5 | +1.5a
| ||||
Roehrborn et al. [24] | Multicenter randomized, double-blind, placebo-controlled | Terazosin 1–10 mg od Placebo | 52 | 976 | −37.8a
| +2.2a
|
973 | −18.4 | +0.7 | ||||
Van Kerrebroeck et al. [37] | Randomized, double-blind, placebo-controlled | Alfuzosin 10 mg od Alfuzosin 2.5 mg tid Placebo | 12 | 143 | −6.9a
| +2.3a
|
150 | −6.4a
| +3.2a
| ||||
154 | −4.9 | +1.4 | ||||
Kirby et al. [38] | Integrated analysis of two multicenter, randomized, double-blind, placebo-controlled studies | Doxazosin 1× 1–8 mg IR Doxazosin 1× 4–8 mg GITS Placebo | 13 | 640 | −8.0a
| +2.6a
|
651 | −7.9a
| +2.8a
| ||||
155 | −5.8 | +1.1 | ||||
Griwan et al. [39] | Randomized, controlled | Naftopidil 75 mg od Tamsulosin 0.4 mg od | 12 | 60 | −9.38 | +1.12 |
60 | −9.8 | +1.87 |